Scientists in Japan have discovered why patients, who are suffering from advanced kidney disease, and undergoing hemodialysis are at high risk to heart attacks and other cardiovascular complications.
New research findings show that uremic toxins, which are not removed by hemodialysis, increase heart attack risk.
The same scientists also found what reduces this risk: an oral adsorbent called "AST-120."
Masayuki Yoshida, M.D., a researcher involved in the work from the Life Science and Bioethics Research Center at Tokyo Medical and Dental University in Tokyo, Japan, said "treatment with AST-120, an oral adsorbent, will not only delay the progression of kidney disease, but may also prevent future heart attack.
For the research, scientists used two groups of mice with kidney failure.
The first group received AST-120 and the second group did not. When monocytes taken from both sets of mice were subjected to flow cytometry, Mac-1 expression and oxidative stress was reduced in the group with AST-120.
The research findings have been published in the Journal of Leukocyte Biology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
